← 返回专利悬崖列表
CAS 110-91-8
morpholineDiethylene oximide1-Oxa-4-azacyclohexane
登记编号：APIX-012、CARF-022、PEMIGA-027、SOTA-004、COBI-025、Timolol Maleate-007、IXAB-012、(IV) 920279-1-a、(III) 920279-2-a、(II) 920279-3-a、LINE-002、CELE-008 等 14 个
应用背景（按来源药适应症）
肺栓塞阿哌沙班静脉血栓形成阿哌沙班Paget-Schroetter综合征阿哌沙班静脉血栓栓塞阿哌沙班血栓形成阿哌沙班栓塞阿哌沙班多发性骨髓瘤卡非佐米骨髓瘤佩米替尼淋巴瘤佩米替尼胆管癌佩米替尼胆管上皮癌佩米替尼胆道癌佩米替尼二型糖尿病索格列净慢性肾功能不全索格列净心脏衰竭索格列净HIV感染考比司他非小细胞肺癌考比司他获得性免疫缺损综合征考比司他高眼压酒石酸溴莫尼定/马来酸噻吗洛尔青光眼酒石酸溴莫尼定/马来酸噻吗洛尔乳腺癌伊沙匹隆转移性乳腺癌伊沙匹隆宫颈癌伊沙匹隆前列腺癌伊沙匹隆实体瘤伊沙匹隆中性粒细胞减少伊沙匹隆高眼压贝美前列素/马来酸噻吗洛尔开角型青光眼贝美前列素/马来酸噻吗洛尔青光眼贝美前列素/马来酸噻吗洛尔高眼压马来酸噻吗洛尔青光眼马来酸噻吗洛尔开角型青光眼马来酸噻吗洛尔创伤和损伤马来酸噻吗洛尔高血压马来酸噻吗洛尔偏头痛马来酸噻吗洛尔非小细胞肺癌甲磺酸兰泽替尼肝功能衰退甲磺酸兰泽替尼非复杂性皮肤和皮肤结构感染利奈唑胺肺炎利奈唑胺复杂皮肤和皮肤结构感染利奈唑胺菌血症利奈唑胺细菌感染利奈唑胺医疗保健相关性肺炎利奈唑胺疼痛塞来昔布炎性疾病塞来昔布关节周围炎塞来昔布肌腱炎塞来昔布颈肩腕综合征塞来昔布腰痛塞来昔布慢性肾功能不全莫立司他钠贫血莫立司他钠肾脏疾病莫立司他钠高胆固醇血症Anacetrapib心脏和血管疾病Anacetrapib血脂障碍Anacetrapib动脉粥样硬化AnacetrapibII型高脂蛋白血症Anacetrapib纯合子家族性高胆固醇血症Anacetrapib
来源药（使用该中间体的合成路线）
| 品种 | 梯队 | 到期年 |
|---|---|---|
| 阿哌沙班Apixaban | Tier A · 立即攻坚 | 2028 |
| 卡非佐米Carfilzomib | Tier B · 提前布局 | 2029 |
| 佩米替尼Pemigatinib | Tier C · 观察 / 贸易 | 2032 |
| 索格列净Sotagliflozin | Tier C · 观察 / 贸易 | 2032 |
| 考比司他Cobicistat | Tier C · 观察 / 贸易 | - |
| 酒石酸溴莫尼定/马来酸噻吗洛尔Brimonidine Tartrate/Timolol Maleate | Tier C · 观察 / 贸易 | - |
| 伊沙匹隆Ixabepilone | Tier C · 观察 / 贸易 | - |
| 贝美前列素/马来酸噻吗洛尔Bimatoprost/Timolol Maleate | Tier C · 观察 / 贸易 | - |
| 马来酸噻吗洛尔Timolol Maleate | Tier C · 观察 / 贸易 | - |
| 甲磺酸兰泽替尼Lazertinib Mesylate | Tier C · 观察 / 贸易 | - |
| 利奈唑胺Linezolid | Tier B · 提前布局 | - |
| 塞来昔布Celecoxib | Tier B · 提前布局 | - |
| 莫立司他钠Molidustat Sodium | Tier C · 观察 / 贸易 | - |
| Anacetrapib | Tier C · 观察 / 贸易 | - |
合成路线中的位置（上下游链）
按路线登记顺序排列，左→右为合成方向；高亮为当前 CAS，其余可点击跳转对应档案。
1-(4-iodophenyl)piperidin-2-one→ethyl (Z)-2-chloro-2-(2-(4-methoxyphenyl)hydrazono)acetate→piperidin-2-one→3,3-dichloropiperidin-2-one→3-chloro-5,6-dihydropyridin-2(1H)-one→morpholine→3-morpholino-5,6-dihydropyridin-2(1H)-one→ethyl 1-(4-methoxyphenyl)-7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylate→1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid
4-iodoaniline→1-(4-iodophenyl)piperidin-2-one→3,3-dichloro-1-(4-iodophenyl)piperidin-2-one→1-(4-iodophenyl)-3-morpholino-5,6-dihydropyridin-2(1H)-one→ethyl (Z)-2-chloro-2-(2-(4-methoxyphenyl)hydrazono)acetate→piperidin-2-one→ethyl 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylate→morpholine→5-bromopentanoic acid→5-bromo-N-(4-iodophenyl)pentanamide→3-chloro-1-(4-iodophenyl)-5,6-dihydropyridin-2(1H)-one→3-morpholino-1-(4-(2-oxopiperidin-1-yl)phenyl)-5,6-dihydropyridin-2(1H)-one
(tert-butoxycarbonyl)-L-leucine→(S)-2-((tert-butoxycarbonyl)amino)-4-phenylbutanoic acid→((S)-2-(2-morpholinoacetamido)-4-phenylbutanoyl)-L-leucyl-L-phenylalanine→(S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxopentan-2-aminium 2,2,2-trifluoroacetate→tert-butyl (S)-(1-(methoxy(methyl)amino)-4-methyl-1-oxopentan-2-yl)carbamate→tert-butyl (S)-(2,6-dimethyl-3-oxohept-1-en-4-yl)carbamate→tert-butyl ((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)carbamate→(S)-methyl 2-amino-3-phenylpropanoate→methyl (tert-butoxycarbonyl)-L-leucyl-L-phenylalaninate→(S)-1-(((S)-1-methoxy-1-oxo-3-phenylpropan-2-yl)amino)-4-methyl-1-oxopentan-2-aminium 2,2,2-trifluoroacetate→methyl ((S)-2-((tert-butoxycarbonyl)amino)-4-phenylbutanoyl)-L-leucyl-L-phenylalaninate→2-chloroacetyl chloride→methyl ((S)-2-(2-chloroacetamido)-4-phenylbutanoyl)-L-leucyl-L-phenylalaninate→morpholine→methyl ((S)-2-(2-morpholinoacetamido)-4-phenylbutanoyl)-L-leucyl-L-phenylalaninate→N,O-dimethylhydroxylamine hydrochloride→prop-1-en-2-ylmagnesium bromide
4-chloro-1H-pyrrolo[2,3-b]pyridine→4-chloro-1-(triisopropylsilyl)-1H-pyrrolo[2,3-b]pyridine→4-chloro-1H-pyrrolo[2,3-b]pyridine-5-carbaldehyde→4-(ethylamino)-1H-pyrrolo[2,3-b]pyridine-5-carbaldehyde→2,6-difluoro-3,5-dimethoxyaniline→5-(((2,6-difluoro-3,5-dimethoxyphenyl)amino)methyl)-N-ethyl-1H-pyrrolo[2,3-b]pyridin-4-amine→3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one→3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one→3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-2-oxo-7-(phenylsulfonyl)-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-8-carbaldehyde→morpholine→3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholinomethyl)-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one→Pemigatinib
(3S,4R,5S)-tetrahydro-2H-pyran-2,3,4,5-tetraol→(3aS,5S,6R,6aS)-5-(hydroxymethyl)-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-6-ol→(3aS,5R,6S,6aS)-6-hydroxy-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxole-5-carboxylic acid→morpholine→((3aS,5R,6S,6aS)-6-hydroxy-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-yl)(morpholino)methanone→1-chloro-2-(4-ethoxybenzyl)-4-iodobenzene→(4-chloro-3-(4-ethoxybenzyl)phenyl)((3aS,5R,6S,6aS)-6-hydroxy-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-yl)methanone→(2S,3S,4R,5R,6S)-6-(4-chloro-3-(4-ethoxybenzyl)phenyl)tetrahydro-2H-pyran-2,3,4,5-tetraol→(2R,3S,4R,5S,6S)-6-(4-chloro-3-(4-ethoxybenzyl)phenyl)tetrahydro-2H-pyran-2,3,4,5-tetrayl tetraacetate→(2S,3S,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triyl triacetate→2-chloro-5-iodobenzoic acid→2-chloro-5-iodobenzoyl chloride→ethoxybenzene→(2-chloro-5-iodophenyl)(4-ethoxyphenyl)methanone
本站可供应的对应中间体
同 CAS 多家在售供应横向对比；价格区间为供应方挂牌口径，实价以询价确认为准。
本页为中间体 CAS 注册档案：同 CAS 的多条路线登记已合并；后续供应商报价与买方需求以该 CAS 为主键撮合。